| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we evaluated the enhancement of anti-tumor immune responses by EGFR-tyrosine kinase inhibitor (TKI) in non-small cell lung carcinoma cell (NSCLC). Human NSCLC with mutated EGFR produced immunosuppressive cytokines and suppressed human DC function, which were restored by EGFR-TKI pretreatment of NSCLC. EGFR-TKI directly enhanced human DC function in an EGFR-independent manner. Moreover, in vivo administration of EGFR-TKI augmented tumor antigen-specific T cell induction and enhanced anti-tumor effects of immunotherapies. These results indicate that EGFR-TKIs may have an activity to enhance antitumor immune responses for NSCLC by targeting both cancer cells and DC, and combined use of EGFR-TKIs may augment the therapeutic effects of current immunotherapies.
|
